Jazz/UCB's Xyrem shows Phase III promise in fibromyalgia
This article was originally published in Scrip
Executive Summary
UCB and Jazz Pharmaceuticals have announced positive top-line data from the first of two Phase III trials of Xyrem (sodium oxybate/JZP-6), demonstrating that it significantly reduced pain and fatigue and improved daily function in patients with fibromyalgia.